Reduction of Nosocomial Vancomycin -Resistant Enterococci (VRE) Colonization and Infection by Active Surveillance and Intervention of Infection Control

Infection Clinical Trial

Official title:

Reduction of Nosocomial VRE Colonization and Infection by Active Surveillance and Intervention of Infection Control (no)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01201031
• Other study ID #: 98105
• Status: Completed
• Phase: N/A
• First received: September 12, 2010
• Last updated: March 14, 2011
• Start date: April 2010
• Est. completion date: February 2011

Study information

• Verified date: March 2011
• Source: Taipei Medical University WanFang Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Observational

Clinical Trial Summary

Vancomycin -resistant enterococci(VRE) has emerged as one of the most common nosocomial pathogen of health-care associated infection since 1988. Although the new antimicrobial agents such as Tigecycline , Daptomycin, Linezolid have clinically effectiveness for the treatment of VRE, but there was not appropriate drugs for eradicating the colonization of VRE. So the active surveillance and strict contact precaution are the best methods for VRE colonization and transmission.

This is a one year study program, we select a unit as the study site. First month (January) is the prepare period. Therefore , we collect 3 months (from February to April) baseline data, then interrupted one month(May) for the health care worker's infection control education.

Then the intervention period are three months (from June to August), and the last four months(from September to December) are the analysis and evaluation period. In the baseline period, we only do the patient's active surveillance and environmental culture. In the intervention period, beside the patient's active surveillance and environmental culture, we add contact precaution as the infection control method. If patient has VRE infection, we prescribe appropriate antibiotic therapy until the culture result proved no growth of VRE.

The aim of this study is to compare and analyze these two period (baseline period and intervention period) for understanding the transmission, risk factors and carriage rate of VRE, as the important guidelines for the VRE infection control in the future.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: February 2011
• Est. primary completion date: September 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• all patients admitted to RCC unit

Exclusion Criteria:

• if the patients or family refused the exam of anal swab .

Study Design

Observational Model: Case-Only

Related Conditions & MeSH terms

• Communicable Diseases
• Infection

Locations

Country	Name	City	State
Taiwan	Taipei Medical University-WanFang Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Taipei Medical University WanFang Hospital

Country where clinical trial is conducted

Taiwan,